Our Approach
Tablet Format Designed to Unlock Patient Acceptance and Drive Superior Health Outcomes
We leverage our N-Tab™ platform, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Therapeutic Areas
First-in-Class Oral Therapies in Daily Tablet Form to Address Unmet Medical Needs
EB613 (oral PTH(1-34)) is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34), teriparatide tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture.
We are developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
About us
Entera is Daring Courageous Fierce
Bringing together scientific excellence and drug development expertise to deliver breakthrough oral therapies
Events
Mollis odio non blandit blandit. Suspendisse ut sem vitae sem malesuada auctor vitae in dolor.
Publication and Events
Shaping the Future of Tablet-Based Therapies: From Peer-Reviewed Research to Industry Events and Publications
- September 15, 2025
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congresse Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- September 8, 2025
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- July 28, 2025
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Share chart
Lorem ipsum dolor sit amet,
In vitae orci fringilla, dignissim nulla quis, faucibus turpis. In vitae ex sapien. Suspendisse pretium porttitor tellus ac convallis.
